We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Medical sector has struggled in 2023, down roughly 5% YTD and underperforming relative to the S&P 500.
One stock residing in the realm, Pfizer (PFE - Free Report) , has seen its near-term outlook shift negative over the last several months, pushing the stock down into a Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, well-known for its COVID-19 vaccine. How does the company currently stack up? Let’s take a closer look.
Share Performance
PFE shares have been in a downward trend throughout 2023, losing more than 20% in value and widely underperforming relative to the S&P 500.
Image Source: Zacks Investment Research
And over the last six months, PFE shares have again lagged behind the general market, losing 6% in value compared to the S&P 500’s 9% gain. The adverse price action indicates that sellers have been in control with no meaningful buying yet to step up.
Quarterly Performance
Pfizer has consistently posted better-than-expected results recently, exceeding earnings and revenue estimates in three consecutive quarters. Just in its latest release, the pharmaceutical titan penciled in a 10% bottom line beat and reported sales marginally above expectations.
Image Source: Zacks Investment Research
However, the market wasn’t impressed with the recent double-beat, sending shares downward post-earnings. This is illustrated by the green arrow circled in the chart below.
Image Source: Zacks Investment Research
Dividends
Pfizer shares do pay a solid dividend, currently yielding 4.1% annually. As we can see, the current yield is more than double the average of the Zacks Medical sector.
Over the last five years, PFE’s payout has grown by roughly 4%.
Image Source: Zacks Investment Research
Bottom Line
Weak share performance and negative earnings estimate revisions from analysts paint a challenging picture for the company’s shares in the near term.
Pfizer (PFE - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook over the last several months.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Pfizer Inc. (PFE)
The Zacks Medical sector has struggled in 2023, down roughly 5% YTD and underperforming relative to the S&P 500.
One stock residing in the realm, Pfizer (PFE - Free Report) , has seen its near-term outlook shift negative over the last several months, pushing the stock down into a Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, well-known for its COVID-19 vaccine. How does the company currently stack up? Let’s take a closer look.
Share Performance
PFE shares have been in a downward trend throughout 2023, losing more than 20% in value and widely underperforming relative to the S&P 500.
Image Source: Zacks Investment Research
And over the last six months, PFE shares have again lagged behind the general market, losing 6% in value compared to the S&P 500’s 9% gain. The adverse price action indicates that sellers have been in control with no meaningful buying yet to step up.
Quarterly Performance
Pfizer has consistently posted better-than-expected results recently, exceeding earnings and revenue estimates in three consecutive quarters. Just in its latest release, the pharmaceutical titan penciled in a 10% bottom line beat and reported sales marginally above expectations.
Image Source: Zacks Investment Research
However, the market wasn’t impressed with the recent double-beat, sending shares downward post-earnings. This is illustrated by the green arrow circled in the chart below.
Image Source: Zacks Investment Research
Dividends
Pfizer shares do pay a solid dividend, currently yielding 4.1% annually. As we can see, the current yield is more than double the average of the Zacks Medical sector.
Over the last five years, PFE’s payout has grown by roughly 4%.
Image Source: Zacks Investment Research
Bottom Line
Weak share performance and negative earnings estimate revisions from analysts paint a challenging picture for the company’s shares in the near term.
Pfizer (PFE - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook over the last several months.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.